IRIS Institutional Research Information System - OPENBS Open Archive UniBS

FOCA', EMANUELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.558
AS - Asia 5.601
EU - Europa 4.663
SA - Sud America 1.084
Continente sconosciuto - Info sul continente non disponibili 454
AF - Africa 179
OC - Oceania 22
AN - Antartide 1
Totale 22.562
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.292
SG - Singapore 1.990
CN - Cina 1.599
IT - Italia 1.146
BR - Brasile 896
DE - Germania 695
UA - Ucraina 687
HK - Hong Kong 684
VN - Vietnam 418
PL - Polonia 393
GB - Regno Unito 343
FI - Finlandia 341
FR - Francia 275
RU - Federazione Russa 237
BD - Bangladesh 226
TR - Turchia 201
IE - Irlanda 157
IN - India 144
CA - Canada 138
NL - Olanda 97
MX - Messico 74
AR - Argentina 65
SE - Svezia 65
JP - Giappone 58
ES - Italia 46
ZA - Sudafrica 45
BF - Burkina Faso 41
ID - Indonesia 41
AT - Austria 40
IQ - Iraq 38
CZ - Repubblica Ceca 32
EC - Ecuador 24
PK - Pakistan 24
SA - Arabia Saudita 24
AU - Australia 20
CL - Cile 20
VE - Venezuela 19
BE - Belgio 18
CO - Colombia 18
LT - Lituania 18
JO - Giordania 17
UZ - Uzbekistan 16
AE - Emirati Arabi Uniti 15
NG - Nigeria 15
EU - Europa 14
IL - Israele 13
JM - Giamaica 13
MA - Marocco 13
PY - Paraguay 13
CH - Svizzera 12
EG - Egitto 12
PE - Perù 12
KE - Kenya 11
TN - Tunisia 11
AZ - Azerbaigian 10
CR - Costa Rica 10
PT - Portogallo 9
UY - Uruguay 9
KZ - Kazakistan 7
MY - Malesia 7
PH - Filippine 7
TT - Trinidad e Tobago 7
BO - Bolivia 6
GR - Grecia 6
HN - Honduras 6
IR - Iran 6
KR - Corea 6
LK - Sri Lanka 6
TH - Thailandia 6
BG - Bulgaria 5
CI - Costa d'Avorio 5
NP - Nepal 5
PA - Panama 5
SK - Slovacchia (Repubblica Slovacca) 5
BH - Bahrain 4
BY - Bielorussia 4
ET - Etiopia 4
GE - Georgia 4
GT - Guatemala 4
HR - Croazia 4
KG - Kirghizistan 4
LV - Lettonia 4
MK - Macedonia 4
UG - Uganda 4
AM - Armenia 3
CG - Congo 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
HU - Ungheria 3
LB - Libano 3
MU - Mauritius 3
NO - Norvegia 3
OM - Oman 3
RO - Romania 3
SY - Repubblica araba siriana 3
AL - Albania 2
CM - Camerun 2
DK - Danimarca 2
EE - Estonia 2
GY - Guiana 2
Totale 22.092
Salva come PNG Salva come JPEG
Città #
Singapore 1.044
Ashburn 1.007
Fairfield 842
Hong Kong 679
Woodbridge 618
Jacksonville 526
San Jose 516
Houston 426
Chandler 396
Warsaw 384
Seattle 365
Beijing 347
New York 347
The Dalles 343
Wilmington 343
Ann Arbor 319
Cambridge 299
Princeton 269
Los Angeles 252
Helsinki 230
Council Bluffs 214
Dallas 172
Lauterbourg 169
Brescia 166
Nanjing 166
Istanbul 162
Munich 159
Dublin 154
Ho Chi Minh City 147
Columbus 108
Milan 101
Buffalo 91
Des Moines 81
Shanghai 78
Moscow 76
Santa Clara 76
Chicago 74
San Francisco 72
São Paulo 71
Hanoi 70
Orem 65
Redondo Beach 65
Dearborn 62
Tokyo 54
Nanchang 53
Tianjin 52
San Diego 51
Frankfurt am Main 49
London 49
Changsha 47
Turku 47
Jinan 45
Shenyang 45
Montreal 41
Toronto 41
Ouagadougou 40
Phoenix 40
Hebei 37
Rome 37
Chennai 36
Nuremberg 36
Denver 34
Lancaster 34
Atlanta 33
Brooklyn 33
Amsterdam 32
Boardman 32
Hangzhou 29
Rio de Janeiro 28
Belo Horizonte 27
Boston 26
Poplar 26
Zhengzhou 26
Jiaxing 25
Mexico City 25
Johannesburg 24
Brno 23
Düsseldorf 23
Haiphong 23
Stockholm 23
Manchester 22
Mumbai 21
Vienna 21
Bologna 20
Charlotte 20
Ningbo 20
Romola 19
Dhaka 18
Kunming 18
Paris 18
Salt Lake City 18
Taizhou 18
Washington 18
Brussels 17
Curitiba 17
Newark 17
Verona 17
Baghdad 16
Brasília 16
Dong Ket 16
Totale 13.844
Salva come PNG Salva come JPEG
Nome #
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 494
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses 371
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study 279
Calculated Decisions: Brescia-COVID Respiratory Severity Scale (BCRSS)/Algorithm 253
Effectiveness of routine lumbar puncture in patients with HIV-associated Dementia (HAD) receiving suppressive antiretroviral treatment 247
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz 244
The Disagreement Among Methods to Evaluate Glomerular Filtration Rate in HIV-Infected Patients Naive to Antiretroviral Therapy. 234
Cohort profile: Standardized management of antiretroviral therapy cohort (MASTER cohort) 227
Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study. 222
Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy 221
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 208
Prevalence of integrase strand transfer inhibitors (InSTIs) resistance mutations in InSTIs-naive and -experienced HIV-1 infected patients: a single Center experience 206
Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study 206
Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy 203
Clinical and Immunological outcomes according to adherence to first-line HAART in a urban and rural cohort of HIV-infected patients in Burkina Faso, West Africa 202
Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection 200
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: A substudy of the NEAT001/ANRS143 randomised trial 192
Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study 191
Cryptogenic liver diseases: sailing by sight from HIV co-infection with hepatitis viruses to HIV mono-infection through the Pillars of Hercules. 190
Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. 184
Virological effectiveness and CD4+ T-cell increase over early andlate courses in HIV infected patients on antiretroviral therapy: focus on HCV andanchor class received 183
Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012 177
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: A Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 177
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART 173
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: Routine evidence from the Italian MASTER Cohort 173
Comparison between the gold standard DXA with calcaneal quantitative ultrasound based-strategy (QUS) to detect osteoporosis in an HIV infected cohort 169
Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction? 168
UVA1 phototherapy as a treatment option for plaque psoriasis in HIV-positive patients 168
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus 167
Disseminated Histoplasmosis as AIDS-presentation. Case Report and Comprehensive Review of Current Literature 165
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients 164
DTG prescribing patterns in PLWH ≥65 years: the impact of 2DR and weight gain 163
Coinfezione HIV/HBV in Burkina Faso, Africa Occidentalele 162
For timing of HAART is less more? CD4+/CD8+ ratio and CD4+ percentage as surrogate markers for more complex immunological features. 161
Long-lasting humoral immune response induced in HIV-1-infected patients by a synthetic peptide (AT20) derived from the HIV-1 matrix protein p17 functional epitope. 161
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: A MASTER cohort study 161
Prevalence of non-B HIV-1 subtypes in North Italy and analysis of transmission clusters based on sequence data analysis 160
Effectiveness of kidney transplantation in HIV-infected recipients under combination antiretroviral therapy: a single-cohort experience (Brescia, Northern Italy) 159
Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy 156
Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study 155
Phenotypic and genotypic evaluation of slime production by conventional and molecular microbiological techniques 154
Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naïve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir 152
Serological Response to SARS-CoV-2 in Health Care Workers Employed in a Large Tertiary Hospital in Lombardy, Northern Italy 150
Impact of detectable human cytomegalovirus DNAemia on viro-immunologicaleffectiveness of HAART in HIV-infected patients naive to antiretroviral therapy 150
Elderly women with human immunodeficiency virus infection: is there an effect of the virus on neuropsychological prolife? 150
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort 149
Clinical presentation and outcomes of SARS-CoV-2 related encephalitis: the ENCOVID multicentre study 149
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 147
Adverse events associated to HAART in Burkina Faso 145
High prevalence of radiological vertebral fractures in HIV-infected males 145
Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter study. 145
Pharmacokinetic Changes during Pregnancy According to Genetic Variants: A Prospective Study in HIV-infected Patients Receiving Atazanavir/Ritonavir 145
Perinatally HIV-Infected Youths After Transition from Pediatric to Adult Care, a Single-Center Experience from Northern Italy 143
Coming home to be cared. Emigration and antiretroviral treatment in the Nanoro health district, Burkina Faso. 142
Management of neurocysticercosis in Northern Italy: presentation of 11 cases and review of the literature on an emerging infection 141
Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV 140
Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy 139
Malaria and HIV in adults: When the parasite runs into the virus 139
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 138
Malaria prophylaxis. A comprehensive review 137
Low-dose Lung Radiotherapy for COVID-19-related Pneumonia: Preliminary Results of the Italian Mono-institutional COLOR-19 Trial 134
HIV/HBV and HIV/HCV co-infection in Burkina Faso, West Africa 133
Steroid-Responsive Encephalitis in Coronavirus Disease 2019 133
Qualitative and quantitative analysis of mortality and morbidity at the health facilities in the rural district of Nanoro, Burkina Faso 132
Drug-specific risk of adverse events onset related to HAART in a resource-limited setting from 2001 to 2009: the experience of 3 medical centers in Burkina Faso 131
Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: An Italian randomized clinical trial 131
The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years 131
Prognostic role of inflammatory biomarkers in HIV-infected patients with a first diagnosis of Hepatocellular carcinoma (HCC): a single-centre study 131
Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover 129
Disengagement and reengagement of HIV continuum of care in a single center cohort in northern Italy 128
The use of ultrasonography, transient elestography, APRI and FIB-4 to measure liver steatosis and fibrosis in HIV-positive patients not co-infected with hepatitis viruses with hypertransaminasemia of unknown origin on HAART 125
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 125
Coming home to be cared. Emigration and antiretroviral treatment in the Nanoro health District, Burkina Faso 124
SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses 124
Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features 123
International migrations and HIV care in the rural District of Nanoro, Burkina Faso 123
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 122
Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions? 122
Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection. 121
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: Results of a 3-year cohort study 121
Laboratory considerations amidst the coronavirus disease 2019 outbreak: the Spedali Civili in Brescia experience 120
Amebiasi e infezione da amebe a vita libera 118
The good, the bad and the ugly: Determinants of antiretroviral-associated toxicities 118
An HIV elite controller patient carrying the homozygous H63D variant in the homeostatic iron regulator gene: A case report 118
Virological Effectiveness of Dolutegravir Plus Darunavir in People with Multi-Drug-Resistant HIV: Data from the PRESTIGIO Registry 116
Infezioni intestinali da protozoi e tricomoniasi 116
Impact of genotypic susceptibility score on cART outcomes during primary HIV infection 115
Immunological Evolution of a Cohort of HIV-2 Infected Patients: Peculiarities of an Underestimated Infection 114
Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-Infected Patients 114
Pregnancy related immune-deficit in HIV-infected pregnant women in resource-limited countries. Implications for HAART initiation 112
Monitoring the toxicity related to HAART from 2001 to 2009 in Burkina Faso: clinical adverse events vs. laboratori adverse events: prevalence, grading and outcome 112
Unboosted Atazanavir for Treatment ofHIV Infection: Rationale and Recommendations for Use 112
The impact of time since SARS-Cov-2 vaccination, age, sex and comorbidities on COVID-19 outcome in hospitalized patients with SARS-CoV-2 infection 111
User fees and compliance to HAART in Ouagadougou, Burkina Faso 111
Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian “GEPPO” Cohort 111
HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide 109
Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic 109
A 2021 update on syphilis: Taking stock from pathogenesis to vaccines 109
Chronic Hepatitis C Cascade of Care in Prisoners—Is There Still Some Work to Do? Analysis of Two Large Penitentiaries in Northern Italy 108
Presence of V72I, G123S and R127K Integrase Inhibitor polymorphisms could reduce ART effectiveness: a retrospective longitudinal study 108
Totale 15.800
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.832
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.832
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.123 0 156 25 77 42 71 74 89 67 134 103 285
2022/20231.187 157 19 23 82 112 293 5 124 218 10 77 67
2023/20241.449 91 27 124 107 67 272 64 62 317 25 54 239
2024/20253.566 41 36 41 447 322 330 292 157 426 346 677 451
2025/20267.642 697 856 512 1.133 937 552 1.054 278 450 606 360 207
2026/2027837 437 400 0 0 0 0 0 0 0 0 0 0
Totale 22.562